Spyre Therapeutics, Inc. — Director's Dealing 2017

Jun 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-06-16

Reporting Person: Schuchart Aaron (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-16	Employee Stock Option (right to buy)	$3.5	A	100000	Acquired	2027-06-15	Common Stock (100000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on May 22, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.